User login
Key clinical point: Under real-world settings, dupilumab was an effective and safe therapeutic option for adolescents and adults with moderate-to-severe atopic dermatitis (AD).
Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 53.3% and 79.4% of patients at weeks 12 and 48, respectively. Overall, mild adverse events were reported by 32% of patients, with the most frequent being conjunctivitis, persistent facial erythema, and arthritis/arthralgia.
Study details: Findings are from a nationwide, retrospective 48-week study including 169 patients aged 12 years or older with moderate-to-severe AD who received dupilumab.
Disclosures: This study did not report any source of funding. Some authors declared serving as a speakers and principal investigators or receiving consulting fees, research grants, and honoraria from several sources.
Source: Torres T et al. J Dermatolog Treat. 2022 (Jan 31). Doi: 10.1080/09546634.2022.2035309
Key clinical point: Under real-world settings, dupilumab was an effective and safe therapeutic option for adolescents and adults with moderate-to-severe atopic dermatitis (AD).
Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 53.3% and 79.4% of patients at weeks 12 and 48, respectively. Overall, mild adverse events were reported by 32% of patients, with the most frequent being conjunctivitis, persistent facial erythema, and arthritis/arthralgia.
Study details: Findings are from a nationwide, retrospective 48-week study including 169 patients aged 12 years or older with moderate-to-severe AD who received dupilumab.
Disclosures: This study did not report any source of funding. Some authors declared serving as a speakers and principal investigators or receiving consulting fees, research grants, and honoraria from several sources.
Source: Torres T et al. J Dermatolog Treat. 2022 (Jan 31). Doi: 10.1080/09546634.2022.2035309
Key clinical point: Under real-world settings, dupilumab was an effective and safe therapeutic option for adolescents and adults with moderate-to-severe atopic dermatitis (AD).
Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 53.3% and 79.4% of patients at weeks 12 and 48, respectively. Overall, mild adverse events were reported by 32% of patients, with the most frequent being conjunctivitis, persistent facial erythema, and arthritis/arthralgia.
Study details: Findings are from a nationwide, retrospective 48-week study including 169 patients aged 12 years or older with moderate-to-severe AD who received dupilumab.
Disclosures: This study did not report any source of funding. Some authors declared serving as a speakers and principal investigators or receiving consulting fees, research grants, and honoraria from several sources.
Source: Torres T et al. J Dermatolog Treat. 2022 (Jan 31). Doi: 10.1080/09546634.2022.2035309